Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy

Cabozantinib in combination with atezolizumab is in clinical development for the treatment of cancer that
started in the prostate, has spread to another part of the body (metastatic), and no longer responds to
hormone treatment options (castration-resistant). The prostate is a small gland in a man’s pelvis and is
involved in the male reproductive system. Symptoms of prostate cancer include an increased need and
difficulty urinating and a feeling that the bladder is not fully empty. The castration-resistant form of
metastatic prostate cancer is particularly hard to treat with limited options and has a high mortality rate so new and additional treatment options are needed.